Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of…
News
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes…
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
Ovid Therapeutics Added to Russell 3000® Index
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic…
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO,…
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Cidara Therapeutics Added to Russell Microcap® Index
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system…
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Dosing of the first subject with BB-301 is expected in the second half of 2023,…
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up…
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
– Sutro will receive $140 million upfront and is eligible to receive up to an…
Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
R&D Retina Day featuring several retina experts will take place from 10:00 AM – 12:00…
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients…
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients…
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
POINT’s vertically integrated platform together with AdvanCell’s lead-212 (²¹²Pb) generator technology enables both the development…
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification…
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and…
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant…